Evaluation of an Herbal-Based De-Pigmenting System (NCT02138539) | Clinical Trial Compass
CompletedPhase 4
Evaluation of an Herbal-Based De-Pigmenting System
United States28 participantsStarted 2013-10
Plain-language summary
The purpose of this study is to evaluate the effectiveness and tolerability of an herbal de-pigmenting regimen applied to one side of the face compared with hydroquinone applied to the other side of the face in treating mottled hyperpigmentation and melasma.
Who can participate
Age range30 Years – 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female age 30-65
* Must be in good general health
* Must be willing to use sunscreen on the face daily
* Must be willing to avoid tanning beds and excessive exposure to direct sunlight
* Must be willing to continue using regular cosmetic regimen
Exclusion Criteria:
* Nursing pregnant/ planning to become pregnant during the course of the study
* Using a medication that increases sensitivity to sunlight including doxycycline, minocycline, tetracycline, ciprofloxin, hydrochlorothiazide, and sulfonamides.
* Any known allergies/sensitivities to facial skincare products, anti-aging products, de-pigmenting products, or products containing hydroquinone
* Usage of any new skincare products during the course of the study
* Presence of atopic dermatitis or psoriasis on the face
* Uncontrolled diabetes, hypertension, hypothyroidism, hyperthyroidism
* TCA or other deep peels within 1 year or medium to light peels within 3 months prior to starting the study
* Facial/laser treatment within the last 3 months
* Facial cosmetic surgery within the last 12 months
* Use of product, topical, or systemic medication, known to affect dyschromia, having "whitening" or anti-aging properties
* Physical skin conditions such as excessive hair, scarring, tattoos that might impair evaluations of the test sites
* Active hepatitis, immune deficiency, or autoimmune disease